View Item 

Show simple item record

Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’
dc.contributor.authorMichelson, Alan D.en_US
dc.contributor.authorLinden, M. D.en_US
dc.contributor.authorFurman, Mark I.en_US
dc.contributor.authorLi, Y.en_US
dc.contributor.authorBarnard, M. R.en_US
dc.contributor.authorFox, M. L.en_US
dc.contributor.authorLau, W. C.en_US
dc.contributor.authorMcLaughlin, T. J.en_US
dc.contributor.authorFrelinger, A. L.en_US
dc.date.accessioned2010-06-01T18:40:09Z
dc.date.available2010-06-01T18:40:09Z
dc.date.issued2007-01en_US
dc.identifier.citationMICHELSON, A. D.; LINDEN, M. D.; FURMAN, M. I.; LI, Y.; BARNARD, M. R.; FOX, M. L.; LAU, W. C.; MCLAUGHLIN, T. J.; FRELINGER, A. L. (2007). "Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’." Journal of Thrombosis and Haemostasis 5(1): 75-81. <http://hdl.handle.net/2027.42/71869>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71869
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17002661&dopt=citationen_US
dc.format.extent705137 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 International Society on Thrombosis and Haemostasisen_US
dc.subject.otherClopidogrelen_US
dc.subject.otherClopidogrel Resistanceen_US
dc.subject.otherPlateletsen_US
dc.titleEvidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum§ Department of Anesthesiology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationother* Center for Platelet Function Studiesen_US
dc.contributor.affiliationotherDivisions of † Pediatric Hematology/Oncology, Department of Pediatricsen_US
dc.contributor.affiliationother† Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MAen_US
dc.contributor.affiliationother¶ Division of Clinical Research, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USAen_US
dc.identifier.pmid17002661en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71869/1/j.1538-7836.2006.02234.x.pdf
dc.identifier.doi10.1111/j.1538-7836.2006.02234.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferencePatrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004; 126: 234S – 64S.en_US
dc.identifier.citedreferenceCurtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 787 – 801.en_US
dc.identifier.citedreferenceMichelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489 – 93.en_US
dc.identifier.citedreferenceGurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908 – 13.en_US
dc.identifier.citedreferenceMatetzky S, Shenkman B, Guetta V, Schechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171 – 5.en_US
dc.identifier.citedreferenceLau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bater ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166 – 71.en_US
dc.identifier.citedreferenceCattaneo M. Aspirin and clopidogrel: efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980 – 7.en_US
dc.identifier.citedreferenceCuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542 – 9.en_US
dc.identifier.citedreferenceGurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 2005; 46: 1827 – 32.en_US
dc.identifier.citedreferenceBarnard MR, Krueger LA, Frelinger III AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. In: Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, et al., eds. Current Protocols in Cytometry. New York: John Wiley & Sons, 2002: 6.10.1 – 6.10.17.en_US
dc.identifier.citedreferenceMichelson AD, Barnard MR, Krueger LA, Frelinger III AL, Furman MI. Flow cytometry. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 297 – 315.en_US
dc.identifier.citedreferenceMichelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533 – 7.en_US
dc.identifier.citedreferenceHato T, Ginsberg MH, Shattil SJ. Integrin alphaIIb-beta3. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 105 – 16.en_US
dc.identifier.citedreferenceMcEver RP. P-selectin/PSGL-1 and other interactions between platelets, leukocytes, and endothelium. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002: 139 – 55.en_US
dc.identifier.citedreferenceKrueger LA, Barnard MR, Frelinger Jr AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. In: Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, et al., eds, Current Protocols in Cytometry. New York: John Wiley & Sons, 2002: 6.10.1 – 6.10.17.en_US
dc.identifier.citedreferenceSchwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461 – 4.en_US
dc.identifier.citedreferenceSerebruany VL, Gurbel PA, Shustov AR, Ohman EM, Topol EJ. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. Am Heart J 1998; 136: 398 – 405.en_US
dc.identifier.citedreferenceFontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989 – 95.en_US
dc.identifier.citedreferenceHetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25: 252 – 7.en_US
dc.identifier.citedreferenceHechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost 2003; 1: 155 – 63.en_US
dc.identifier.citedreferenceAngiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Boss TA, Macaya G. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101 – 8.en_US
dc.identifier.citedreferenceAngiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, Hernandez-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903 – 10.en_US
dc.identifier.citedreferenceSamara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 89 – 94.en_US
dc.identifier.citedreferenceAleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85 – 92.en_US
dc.identifier.citedreferenceMobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 456 – 8.en_US
dc.identifier.citedreferenceGurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets. Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation 2005; 111: 1153 – 9.en_US
dc.identifier.citedreferenceGurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392 – 6.en_US
dc.identifier.citedreferencePatti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099 – 106.en_US
dc.identifier.citedreferenceHochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560 – 4.en_US
dc.identifier.citedreferenceBrandt JT, Payne CD, Weerakkody G, Behounek BD, Naganuma H, Jakubowski JA, Wiriott SD, Winters KJ. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CD-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J Am Coll Cardiol 2005; 45: 87A.en_US
dc.identifier.citedreferenceWiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366 – 73.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2006.02234.x.pdf
Size:
688.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.